Skip to main content
SpringerLink
Log in

Multimodal Therapy for Locally Advanced Esophageal Cancer

  • Chapter
  • First Online:
Esophageal Cancer

  • 202 Accesses

Abstract

The differences in EAC and ESCC as diseases processes has been highlighted by the advancements in neoadjuvant treatment regimens. In our opinion, these two diseases entities should be treated differently. It is clear that chemotherapy or chemoradiotherapy should be given before surgery; however, perioperative systemic regimens have taken over the landscape for patients with EAC in many centers around the world. Although significant regional differences exist, the data suggest that for EAC docetaxel-based therapy given in a perioperative fashion followed by en bloc surgical should be considered the standard of care for this histological subtype. Successful identification of the agent, and patients, who will benefit from immunotherapy or biological agents to the neoadjuvant setting will likely influence future recommendations. For patients with locally advanced ESCC, nCRT followed by surgery seems to be the best treatment option available. The addition of adjuvant checkpoint inhibition in the presence of residual disease seems to be the best augment for this approach. However, significant regional differences exist in this setting as well with docetaxel-based therapy emerging as a viable alternative based on several trials. Finally, selective surgery after induction chemoradiation is also on the horizon for both ESCC and EAC and future studies may provide a foundation for treating certain patients definitively.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Arnott SJ, Duncan W, Gignoux M, Hansen HS, Launois B, Nygaard K, Parmar MK, Rousell A, Spilopoulos G, Stewart G, Tierney JF, Wang M, Rhugang Z, Oeosphageal Cancer Collaborative Group. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev. 2005;2005(4):CD001799. https://doi.org/10.1002/14651858.CD001799.pub2. PMID: 16235286; PMCID: PMC8407511.

  2. Cao XF, He XT, Ji L, Xiao J, Lv J. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus. 2009;22(6):477–81. https://doi.org/10.1111/j.1442-2050.2008.00910.x. PMID: 19703071.

    Article  PubMed  Google Scholar 

  3. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg RJ, Pajak T, Salter M, Benson AB 3rd. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90–12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 1999;43(3):517–23. https://doi.org/10.1016/s0360-3016(98)00463-5. PMID: 10078631.

    Article  CAS  PubMed  Google Scholar 

  4. Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Gedouin D, Boutin D, Campion JP, Launois B. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 1994;73(7):1779–84. https://doi.org/10.1002/1097-0142(19940401)73:7%3c1779::aid-cncr2820730702%3e3.0.co;2-t. PMID: 8137201.

    Article  PubMed  Google Scholar 

  5. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW, Trans-Tasman Radiation Oncology Group, Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005;6(9):659–68. https://doi.org/10.1016/S1470-2045(05)70288-6. PMID: 16129366; Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335(7):462–7. https://doi.org/10.1056/NEJM199608153350702. Erratum in: N Engl J Med 1999 Jul 29;341(5):384. PMID: 8672151.

  6. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335(7):462–7. https://doi.org/10.1056/NEJM199608153350702.Erratum.In:NEnglJMed1999;341(5):384. PMID: 8672151.

    Article  CAS  PubMed  Google Scholar 

  7. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84. https://doi.org/10.1056/NEJMoa1112088. PMID: 22646630.

  8. Shapiro J, van Lanschot J, Hulshof M, van Hagen P, van Berge HM, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8. https://doi.org/10.1016/S1470-2045(15)00040-6.

    Article  PubMed  Google Scholar 

  9. Noordman BJ, van Klaveren D, van Berge Henegouwen MI, Wijnhoven BPL, Gisbertz SS, Lagarde SM, van der Gaast A, Hulshof MCCM, Biermann K, Steyerberg EW, van Lanschot JJB; also on behalf of the CROSS-Study Group. Impact of surgical approach on long-term survival in esophageal adenocarcinoma patients with or without neoadjuvant chemoradiotherapy. Ann Surg. 2018;267(5):892–897. https://doi.org/10.1097/SLA.0000000000002240. PMID: 28350565.

  10. Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J, AME Thoracic Surgery Collaborative Group. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a Phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36(27):2796–2803. https://doi.org/10.1200/JCO.2018.79.1483. Epub 2018 Aug 8. PMID: 30089078; PMCID: PMC6145832.

  11. Mariette C, Dahan L, Mornex F, Maillard E, Thomas P, Meunier B, Boige V, Pezet D, Robb WB, Le Brun-Ly V, et al. Surgery alone versus chemoradiotherapy followed by surgery for Stage I and II esophageal cancer: final analysis of randomized controlled Phase III Trial FFCD 9901. J Clin Oncol. 2014;32:2416–22. https://doi.org/10.1200/JCO.2013.53.6532.

    Article  CAS  PubMed  Google Scholar 

  12. Mantziari S, Gronnier C, Renaud F, Duhamel A, Théreaux J, Brigand C, Carrère N, Lefevre JH, Pasquer A, Demartines N, Collet D, Meunier B, Mariette C, on behalf of the FREGAT working group—FRENCH—AFC. Survival benefit of neoadjuvant treatment in clinical T3N0M0 esophageal cancer: results from a retrospective multicenter European study. Ann Surg. 2017;266(5):805–813. https://doi.org/10.1097/SLA.0000000000002402

  13. Yen YC, Chang JH, Lin WC, Chiou JF, Chang YC, Chang CL, Hsu HL, Chow JM, Yuan KS, Wu ATH, Wu SY. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques. Cancer. 2017;123(11):2043–53. https://doi.org/10.1002/cncr.30565. Epub 2017 Feb 2 PMID: 28152166.

    Article  CAS  PubMed  Google Scholar 

  14. Kato K, Igaki H, Ito Y, et al. Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502). J Clin Oncol. 2019;37(4)7. https://doi.org/10.1200/jco.2019.37.4_suppl.7.

  15. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339(27):1979–84. https://doi.org/10.1056/NEJM199812313392704. PMID: 9869669.

    Article  CAS  PubMed  Google Scholar 

  16. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L, Peracchia A. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. Cancer. 2001;91:2165–74. https://doi.org/10.1002/1097-0142(20010601)91:11%3c2165::AID-CNCR1245%3e3.3.CO;2-8.

    Article  CAS  PubMed  Google Scholar 

  17. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28(35):5210–8. https://doi.org/10.1200/JCO.2009.26.6114. Epub 2010 Nov 8. PMID: 21060024; PMCID: PMC3020693.

  18. Girling DJ, Bancewicz J, Clark PI, et al. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;366(22):2074–84. https://doi.org/10.1016/S0140-6736(02)08651-8.

    Article  Google Scholar 

  19. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. https://doi.org/10.1056/nejmoa055531.

    Article  CAS  PubMed  Google Scholar 

  20. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21. https://doi.org/10.1200/JCO.2010.33.0597. Epub 2011 Mar 28 PMID: 21444866.

    Article  CAS  PubMed  Google Scholar 

  21. Ferri LE, Ades S, Alcindor T, et al. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: A multicenter phase II trial. Ann Oncol. 2012;23(6):1512–7. https://doi.org/10.1093/annonc/mdr465.

    Article  CAS  PubMed  Google Scholar 

  22. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised pahse II/III trian. Lancet. 2019;393(10184):1948–57. https://doi.org/10.1016/S0140-6736(18)32557-1.

    Article  PubMed  Google Scholar 

  23. Donlon NE, Kammili A, Roopnarinesingh R, et al. FLOT-regimen chemotherapy and transthoracic en bloc resection for esophageal and junctional adenocarcinoma. Ann Surg. 2021;274(5):814–20. https://doi.org/10.1097/SLA.0000000000005097.

    Article  PubMed  Google Scholar 

  24. Boonstra JJ, Kok TC, Wijnhoven BPL, et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: Long-term results of a randomized controlled trial. BMC Cancer. 2011;16(9):1090–8. https://doi.org/10.1186/1471-2407-11-181.

    Article  CAS  Google Scholar 

  25. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki HAN, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.

    Article  PubMed  Google Scholar 

  26. Kato K, Ito Y, Daiko H, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol. 2022;40(4)238. https://doi.org/10.1200/JCO.2022.40.4_suppl.238.

  27. Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y, Zeng Z, Zhu J, Hou Y, Du M, Jiao J, Jiang H, Gong L, Li Z, Liu J, Xie D, Li W, Lian C, Zhao Q, Chen C, Zheng B, Liao Y, Li K, Li H, Wu H, Dai L, Chen KN. Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized clinical trial. JAMA Surg. 2021;156(5):444–51. https://doi.org/10.1001/jamasurg.2021.0133.PMID:33729467;PMCID:PMC7970392.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Stahl M, Walz MK, Riera-Knorrenschild J, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial. Eur J Cancer. 2017;81:183–90. https://doi.org/10.1016/j.ejca.2017.04.027.

    Article  CAS  PubMed  Google Scholar 

  29. Klevebro F, Alexandersson von Döbeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, Hatlevoll I, Glenjen NI, Lind P, Tsai JA, Lundell L, Nilsson M. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016;27(4):660–7. https://doi.org/10.1093/annonc/mdw010. Epub 2016 Jan 17. PMID: 26782957.

  30. Reynolds J V., Preston SR, O’Neill B, et al. Neo-AEGIS (neoadjuvant trial in adenocarcinoma of the esophagus and esophago-gastric junction international study): preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (modified MAGIC or FLOT protocol). (NCT01726452). J Clin Oncol. 2021;39(15)4004. https://doi.org/10.1200/jco.2021.39.15_suppl.4004.

  31. Kamarajah SK, Phillips AW, Ferri L, Hofstetter WL, Markar SR. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study. Br J Surg. 2021;108(4):403–11. https://doi.org/10.1093/bjs/znaa121. PMID: 33755097.

    Article  CAS  PubMed  Google Scholar 

  32. Cools-Lartigue J, Markar S, Mueller C, Hofstetter W, Nilsson M, Ilonen I, Soderstrom H, Rasanen J, Gisbertz S, Hanna GB, Elliott J, Reynolds J, Kisiel A, Griffiths E, Van Berge HM, Ferri L. An international cohort study of prognosis associated with pathologically complete response following neoadjuvant chemotherapy versus chemoradiotherapy of surgical treated esophageal adenocarcinoma. Ann Surg. 2022;276(5):799–805. https://doi.org/10.1097/SLA.0000000000005619. Epub 2022 Jul 21 PMID: 35861351.

    Article  PubMed  Google Scholar 

  33. Gronnier C, Tréchot B, Duhamel A, Mabrut JY, Bail JP, Carrere N, Lefevre JH, Brigand C, Vaillant JC, Adham M, Msika S, Demartines N, El Nakadi I, Piessen G, Meunier B, Collet D, Mariette C, FREGAT Working Group-FRENCH-AFC, Luc G, Cabau M, Jougon J, Badic B, Lozach P, Cappeliez S, Lebreton G, Alves A, Flamein R, Pezet D, Pipitone F, Iuga BS, Contival N, Pappalardo E, Mantziari S, Hec F, Vanderbeken M, Tessier W, Briez N, Fredon F, Gainant A, Mathonnet M, Bigourdan JM, Mezoughi S, Ducerf C, Baulieux J, Pasquer A, Baraket O, Poncet G, Vaudoyer D, Enfer J, Villeneuve L, Glehen O, Coste T, Fabre JM, Marchal F, Frisoni R, Ayav A, Brunaud L, Bresler L, Cohen C, Aze O, Venissac N, Pop D, Mouroux J, Donici I, Prudhomme M, Felli E, Lisunfui S, Seman M, Petit GG, Karoui M, Tresallet C, Ménégaux F, Hannoun L, Malgras B, Lantuas D, Pautrat K, Pocard M, Valleur P. Impact of neoadjuvant chemoradiotherapy on postoperative outcomes after esophageal cancer resection: results of a European multicenter study. Ann Surg. 2014;260(5):764–70; discussion 770–1. https://doi.org/10.1097/SLA.0000000000000955. PMID: 25379847.

  34. Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y, Zeng Z, Zhu J, Hou Y, Du M, Jiao J, Jiang H, Gong L, Li Z, Liu J, Xie D, Li W, Lian C, Zhao Q, Chen C, Zheng B, Liao Y, Li K, Li H, Wu H, Dai L, Chen KN. Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized clinical trial. JAMA Surg. 2021;156(5):444–451. https://doi.org/10.1001/jamasurg.2021.0133. PMID: 33729467; PMCID: PMC7970392.Wang DB, Zhang X, Han HL, Xu YJ, Sun DQ, Shi ZL. Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis. Dig Dis Sci. 2012;57(12):3226–33. https://doi.org/10.1007/s10620-012-2263-8. Epub 2012 Jun 14. PMID: 22695886.

  35. Safran HP, Winter K, Ilson DH, et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2022;23(2):259–69. https://doi.org/10.1016/S1470-2045(21)00718-X.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Shah MA, Almhanna K, Iqbal S, et al. Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC). J Clin Oncol. 2021;39(15):4005. https://doi.org/10.1200/jco.2021.39.15_suppl.4005.

    Article  Google Scholar 

  37. Shen D, Chen Q, Wu J, Li J, Tao K, Jiang Y. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. J Gastrointest Oncol. 2021;12(1):1–10. https://doi.org/10.21037/JGO-20-599.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Park SY, Hong MH, Kim HR, et al. The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma. J Thorac Dis. 2020;12(11):6426–34. https://doi.org/10.21037/jtd-20-1088.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Stüben BO, Stuhlfelder J, Kemper M, Tachezy M, Ghadban T, Izbicki JR, Bokemeyer C, Sinn M, Karstens KF, Reeh M. Completion of FLOT therapy, regardless of tumor regression, significantly improves overall survival in patients with esophageal adenocarcinoma. Cancers (Basel). 2022;14(4):1084. https://doi.org/10.3390/cancers14041084.PMID:35205833;PMCID:PMC8870232.

    Article  PubMed  Google Scholar 

  40. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH, CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21. https://doi.org/10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7. PMID: 22226517.

  41. Mokdad AA, Yopp AC, Polanco PM, Mansour JC, Reznik SI, Heitjan DF, Choti MA, Minter RR, Wang SC, Porembka MR. Adjuvant chemotherapy vs postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer: a propensity score-matched analysis. JAMA Oncol. 2018;4(1):31–8. https://doi.org/10.1001/jamaoncol.2017.2805.PMID:28975352;PMCID:PMC5833647.

    Article  PubMed  Google Scholar 

  42. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M, CheckMate 577 Investigators. Adjuvant Nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–1203. https://doi.org/10.1056/NEJMoa2032125. Erratum in: N Engl J Med. 2023 Feb 16;388(7):672. PMID: 33789008.

Download references

Author information

Authors and Affiliations

  1. Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada

    James Tankel & Lorenzo Ferri

Authors
  1. James Tankel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lorenzo Ferri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lorenzo Ferri .

Editor information

Editors and Affiliations

  1. Hospital Alemán of Buenos Aires, University of Buenos Aires, Buenos Aires, Argentina

    Francisco Schlottmann

  2. Department of Surgery and Oncology, McGill University, Montreal, QC, Canada

    Lorenzo Ferri

  3. Thoracic Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Daniela Molena

  4. Department of Surgery, University of Virginia, Charlottesville, VA, USA

    Marco G. Patti

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tankel, J., Ferri, L. (2023). Multimodal Therapy for Locally Advanced Esophageal Cancer. In: Schlottmann, F., Ferri, L., Molena, D., Patti, M.G. (eds) Esophageal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-031-39086-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-39086-9_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-39085-2

  • Online ISBN: 978-3-031-39086-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation